The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...

The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.

ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.

The future of skin cancer treatment looks even more promising. Advances in artificial intelligence (AI) are revolutionizing ...

Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...

One in 12 children globally faces online sexual abuse: Lancet study Approximately one in 12 children worldwide experienced online sexual abuse in the past year, according to a study published in ...

“It took us a few minutes to accept that this pile of rubble was our home,” said Islam Dahliz, whose family was ordered by Israeli forces to evacuate Rafah in May. By Vivian Yee and Bilal ...

Trump Asserts a Muscular Vision of Presidential Power on First Day Back In a flurry of executive actions, President Trump revived disputed claims of broad presidential authority from his first ...

There are seven women who remain on the list of 33 hostages expected to be released from Hamas captivity in the first phase of the hostage deal. Information ...

The Duke of Sussex's privacy case against News Group Newspapers was due to start at the High Court yesterday.